Re: Farmas USA
http://blogs.barrons.com/stockstowatchtoday/2016/04/06/biotech-the-waiting-game/
Recovery in the latter half of the year could be driven by several major data readouts. Although we expect fewer drugs to be approved in 2016 vs. 2015, the pace of major data readouts should pick up in 2H16. We believe that large cap stocks will once again lead the way, with Celgene reporting data from with 18 Phase III trials ($20bn peak sales) starting with the REMARCand RELEVANCE (Revlimid in DLBCL & FL) studies in 3Q16 and 1H17. We also expect Amgen to report data in 4Q16 from the 27,500 patient CV outcomes trial of its cholesterol lowering drug Repatha ($5-7bn) and Gilead to report pivotal Phase II data in 4Q16 for simtuzumab for NASH (>$10bn). We expect Biogen (BIIB) shares to take direction from two earlier stage data readouts, with Phase 1/2 data for opicinumab (MS) in mid-2016 andaducanumab (Alzheimer’s) in 4Q16, as each could support peak sales >$10bn.